Procaps Group Announces New Chairman
June 28 2024 - 8:31AM
Business Wire
Ruben Minski decides to step down as Executive
Chairman and José Minski is appointed as new Chairman of the
Board
Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”),
a leading integrated LatAm healthcare and pharmaceutical
conglomerate, announced that Mr. Ruben Minski has resigned from his
role as Executive Chairman of the Board, effective June 30th. Mr.
Minski will continue to serve as a member of the Board of
Directors.
Reflecting on his decision, Ruben stated: “This month marked six
months since Jose Antonio Vieira assumed the role of CEO of
Procaps. To ensure a smooth and effective transition, I have had
the privilege of serving as Executive Chairman of our Board.
Reflecting on these six months, I believe the transition to our new
leader has been successful, and it is now time for me to step down
from this honorable position. As a major shareholder, I will remain
on the Board of Directors to support our efforts to overcome
obstacles and capitalize on opportunities.”
The Board of Directors of the Company (the “Board”) has
appointed Mr. José Minski, currently a member of the Board and
Chair of the M&A Committee, as the new Chairman of the
Board.
José Minski brings extensive experience and a deep understanding
of Procaps´ strategic direction and operational objectives, which
will be invaluable in his new role. José Minski stated, “I am
honored to take on this new role and look forward to working
closely with the Board and management team to continue driving
Procaps´ strategic initiatives and deliver value to our
shareholders.”
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading
developer of pharmaceutical and nutraceutical solutions, medicines,
and hospital supplies that reach more than 50 countries in all five
continents. Procaps has a direct presence in 13 countries in the
Americas and nearly 5,000 employees working under a sustainable
model. Procaps develops, manufactures, and markets over-the-counter
(OTC) pharmaceutical products, prescription pharmaceutical drugs
(Rx), nutritional supplements, and high-potency clinical
solutions.
For more information, visit www.procapsgroup.com or Procaps’
investor relations website investor.procapsgroup.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240628954592/en/
Investor Contact: Melissa Angelini ir@procapsgroup.com +1
754 260-6476 investor.procapsgroup.com
Procaps (NASDAQ:PROC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Procaps (NASDAQ:PROC)
Historical Stock Chart
From Dec 2023 to Dec 2024